The week in pharma: action, reaction and insight – week to June 16, 2023

18 June 2023

By Barbara Obstoj-Cardwell. Editor

Last week saw the much anticipated Food and Drug Administration (FDA) advisory committee vote in favor of full approval for Eisai and Biogen’s Alzheimer’s disease (AD) treatment Leqembi, which thus far was marketed under an accelerated approval clearance. Also, the FDA granted approval for Japanese drugmaker Daiichi Sankyo’s Injectafer for heart failure patients with iron deficiency. M&A featured, first with Swiss pharma giant Novartis punting up to $3.5 billion to expand its kidney disease portfolio through the acquisition of Chinook Therapeutics and its lead candidates atrasentan and zigakibart. Additionally, Coherus BioSciences last Friday announced it is to acquire fellow USA-based Surface Oncology for around $65 million, with the aim of growing its immuno-oncology assets.

Leqembi taking another step forward

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK